No doubt, the fast development of new drugs has been driving growth at Icon (ICLR), an outsourcer of clinical trials. But the company’s own strategic moves are fueling growth, too. Spending in the drug development industry is growing in the low to mid-single digits, Icon said last month, when it beat second-quarter earnings estimates.